Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

59.74
+0.98001.67%
Pre-market: 60.741.00+1.67%06:15 EDT
Volume:2.72M
Turnover:163.43M
Market Cap:9.93B
PE:-17.17
High:60.92
Open:59.64
Low:59.06
Close:58.76
52wk High:86.74
52wk Low:41.71
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.15
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.58
PE(LYR):-25.09

Loading ...

Ionis Pharmaceuticals Shares Fall 13.8% Premarket After Drug Made in Partnership with Astrazeneca Fails Late-stage Heart Disease Trial

THOMSON REUTERS
·
Jul 09

Movement Alert|Ionis Pharmaceuticals Falls 14.75% in Pre-Market Trading, Phase 3 ATTR-CM Trial for Eplontersen Fails Primary Endpoint

Market Focus
·
Jul 09

Astrazeneca Top Loser on FTSE 100 After Heart Disease Drug Fails Late-stage Trial

Reuters
·
Jul 09

Astrazeneca Shares Set for Their Biggest One-day Fall Since March 2020

THOMSON REUTERS
·
Jul 09

Astrazeneca Shares Down 9% After Late-stage Trial Miss for Nerve Disease Drug Wainua

THOMSON REUTERS
·
Jul 09

European Shares Gain as Tech Stocks Rebound; Middle East in Focus

Reuters
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09

Ionis Says Phase 3 Eplontersen Trial in Attr-cm Misses Primary Endpoint

Reuters
·
Jul 09

Update on Cardio-ttransform Phase 3 Trial of Eplontersen in Adults with Transthyretin-mediated Amyloid Cardiomyopathy

THOMSON REUTERS
·
Jul 09

Ionis Pharmaceuticals - Cardio-ttransform Phase 3 Trial for Eplontersen Misses Primary Endpoint up to Week 140

THOMSON REUTERS
·
Jul 09

Ionis Director Joseph Klein III Disposes of $910,231.42 in Common Shares

Reuters
·
Jul 07

Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone

Simply Wall St.
·
Jul 07

Ionis Completes Enrollment in Pivotal Phase 3 Reveal Cohort for Angelman Drug Obudanersen

Reuters
·
Jul 06

Ionis Pharmaceuticals - to Initiate Phase 3 Champion Study of Obudanersen Before End of 2026

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Topline Data from Reveal Study Expected in Second Half of 2027

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Adult Cohort Expected to Complete Enrollment in Q3 2026

THOMSON REUTERS
·
Jul 06

Ionis Completes Enrollment in Pivotal Cohort of the Phase 3 Reveal Study Evaluating Obudanersen in Angelman Syndrome

THOMSON REUTERS
·
Jul 06

Ionis EVP, Chief Clinical Development Officer Eugene Schneider Disposes of 26,000 Shares for $2.11 Million

Reuters
·
Jul 01

Ionis EVP Research Eric Swayze Sells 10,602 Shares for $839,082.60

Reuters
·
Jun 27

Movement Alert|Ionis Pharmaceuticals Rises 5.32% in Regular Trading, Zilganersen Global Commercialization Accelerates via Recordati Licensing Deal

Market Focus
·
Jun 26